Patient Disease:
Canine Mast Cell Tumor
Study Name:
Combination Radiation Therapy and Gilvetmab for the Treatment of Mast Cell Tumors in Dogs
Purpose of the study:
- To determine the overall response rate (complete response and partial response) for dogs receiving hypofractionated radiation therapy in combination with gilvetmab for non-resectable cutaneous or subcutaneous mast cell tumors (MCT)
Primary Eligibility Criteria:
- Confirmed diagnosis of MCT
- Adequate organ function
- Must be able to safely undergo anesthesia
- Two-month washout from chemotherapy
- No prior treatment with radiation therapy
- Pets must come to CSU for all visits related to the clinical trial
Study Protocol:
- All dogs will be treated with radiation therapy which will be given on Days 0, 7, and 21 of the study
- Gilvetmab will be given as an IV infusion every 2 weeks for up to 10 treatments starting on Day 7
- Visits will be required on Days 0 and 7 and then every 2 weeks until the Day 133 visit
- CBC and chemistry profile will be performed every 4 weeks during gilvetmab treatment
Owner Responsibilities:
- Costs of diagnostics to determine eligibility for the trial
- Make and keep all appointments as required by the clinical trial protocol
Financial Incentives:
- Once enrolled, the study will cover the costs of the radiation therapy and anesthesia ($1140/dog), the recheck blood work at 5 time points ($865/dog), the gilvetmab and administration ($2,200/dog), and 11 recheck exams with clinical trials ($451/dog)
- Up to $500 is available to cover costs of treatment of side effects that may occur
If you have further questions about any of our clinical trials, please submit an online consult form. Your consult will then be directed to our trials team. Requests are typically returned within 5 business days.